Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
NCT05669950 · View on ClinicalTrials.gov ↗
Study Summary
This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.
Conditions Studied
Interventions
- DRUG Lu AG13909
Study Locations (17)
Other
- Rigshospitalet — Copenhagen
- Chu Angers — Angers
- CHU de Lille — Lille
- GH Pitié-Salpêtrière — Paris
- CHRU Strasbourg — Strasbourg
- David Metreveli Medical Centre, Tbilisi — Tbilisi
- Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin — Dublin
- Azienda Ospedaliero Universitaria di Bologna — Bologna
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma — Roma
- Centrum Nowoczesnych Terapii, Dobry Lekarz — Dobry Lekarz
- Sahlgrenska University Hospital — Gothenburg
- Karolinska University Hospital — Stockholm
- NIHR/Wellcome Trust Clinical Research Facility — Birmingham
- Cambridge Clinical Research Centre — Cambridge
- NIHR Clinical Research Facility — London
- University College London Hospital - NIHR — London
Michigan
- University Hospital-University of Michigan — Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669950
The ClinicalTrials.gov registry entry for NCT05669950 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 17 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention — of which Lu AG13909 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05669950 reports 17 study locations spanning 2 distinct geographic areas — top geographies include Other, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05669950 about?
NCT05669950 is a clinical study titled "A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia". This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and...
What is the current status of trial NCT05669950?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-12-19. Estimated completion is 2027-12-31.
What conditions does trial NCT05669950 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05669950?
The interventions under investigation include: Lu AG13909 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05669950?
This trial is sponsored by H. Lundbeck A/S, which has 17 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05669950 being conducted?
This trial has 17 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.